Last updated on April 2019

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol


Brief description of study

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

Detailed Study Description

The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios.

This is multi-center, a non-randomized, natural history, non-treatment study. 1,070-2,000 total participants will be enrolled across three cohorts: cognitively normal* (CN), mild cognitive impairment (MCI) and mild Alzheimer's Disease (AD) dementia. Participants between the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada. Approximately, 700 - 800 will be rollover participants from previous ADNI studies, and 370 - 1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts.

Participants will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years.

*currently recruiting non-Caucasian participants only for the cognitively normal cohort.

Clinical Study Identifier: NCT02854033

Find a site near you

Start Over

University of Wisconsin

Madison, WI United States
  Connect »

Dent Neurologic Institute

Buffalo, NY United States
  Connect »

University of Kansas

Fairway, KS United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Ohio State University

Columbus, OH United States
  Connect »

Rhode Island Hospital

Providence, RI United States
  Connect »

Columbia University

New York, NY United States
  Connect »

University of California, Davis

Walnut Creek, CA United States
  Connect »

University of Pittsburgh

Pittsburgh, PA United States
  Connect »

Mayo Clinic, Rochester

Rochester, MN United States
  Connect »

Georgetown University

Washington, WA United States
  Connect »

Indiana University

Indianapolis, IN United States
  Connect »

University of Southern California

Los Angeles, CA United States
  Connect »

Albany Medical College

Albany, NY United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

Wien Center for Clinical Research

Miami Beach, FL United States
  Connect »

University of Rochester

Rochester, NY United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Houston Methodist

Houston, TX United States
  Connect »

Washington University, St. Louis

Saint Louis, MO United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

University of Iowa

Iowa City, IA United States
  Connect »

Howard University

Washington, WA United States
  Connect »

Mayo Clinic, Jacksonville

Jacksonville, FL United States
  Connect »

University of Kentucky

Lexington, KY United States
  Connect »

Roper St. Francis Hospital

Charleston, SC United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.